Machina Capital S.A.S. Vertex Pharmaceuticals Inc Transaction History

Machina Capital S.A.S.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$392.81 - $485.53 $48,315 - $59,720	123 Added 6.17%	2,117 $992,000
Q1 2024 May 13, 2024	BUY	$407.69 - $446.08 $812,933 - $889,483	1,994 New	1,994 $833,000
Q3 2023 Nov 02, 2023	BUY	$338.18 - $362.46 $794,046 - $851,056	2,348 New	2,348 $816,000
Q1 2023 Apr 24, 2023	SELL	$283.23 - $323.1 $56,646 - $64,620	-200 Reduced 18.18%	900 $283,000
Q4 2022 Feb 08, 2023	BUY	$285.76 - $321.48 $314,336 - $353,628	1,100 New	1,100 $317,000
Q1 2020 May 05, 2020	SELL	$199.77 - $247.81 $695,399 - $862,626	-3,481 Closed	0 $0
Q4 2019 Feb 07, 2020	SELL	$166.71 - $223.91 $208,554 - $280,111	-1,251 Reduced 26.44%	3,481 $762,000
Q3 2019 Nov 12, 2019	SELL	$166.23 - $187.09 $123,508 - $139,007	-743 Reduced 13.57%	4,732 $802,000
Q2 2019 Jul 19, 2019	SELL	$164.61 - $190.37 $1.51 Million - $1.75 Million	-9,172 Reduced 62.62%	5,475 $1 Million
Q1 2019 May 14, 2019	BUY	$163.73 - $194.7 $2.26 Million - $2.68 Million	13,780 Added 1589.39%	14,647 $2.69 Million
Q4 2018 Mar 25, 2019	BUY	$151.91 - $192.21 $131,705 - $166,646	867 New	867 $144,000

1,716

225M

1.19M

1.56M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $129B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Machina Capital S.A.S., based on Form 13F filings with the SEC.

Stay updated on Machina Capital S.A.S. with notifications on news.